Specific COX-2 inhibitors: Perspectives of a therapy with novel analgesic and anti-inflammatory substances;Spezifische COX-2-inhibitoren: Perspektiven einer therapie mit neuen analgetischen und antiinflammatorischen wirkstoffen

Wiener Klinische Wochenschrift

Volumn 111, Issue 3, 1999, Pages 103-112

  Hinz, Burkhard ^a   Brune, Kay ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cyclooxygenase isoforms; Inflammation; Non steroidal anti inflammatory drugs; Pain; Prostaglandins; Specific COX 2 inhibitors

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; ROFECOXIB; UNCLASSIFIED DRUG;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN; CLINICAL TRIAL; COLON CANCER; DRUG INDICATION; DRUG SELECTIVITY; HUMAN; KIDNEY; OSTEOARTHRITIS; PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPINAL CORD;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE III; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; SULFONES; TREATMENT OUTCOME;

EID: 0033548187     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Barnes PJ, Adcock I (1993) Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 14: 436-441
2. Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M (1996) Upregulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390: 165-169
3. Brune K (1974) How aspirin might work: a pharmacokinetic approach. Agents Actions 4: 230-232
4. Brune K (1994) Spinal cord effects of antipyretic analgesics. Drugs 47 [Suppl] 5: 21-27
5. Brune K (1997) The early history of non-opioid analgesics. Acute Pain 1: 33-40
6. Brune K, Hinz B (1998) Selektive Cyclooxygenase-2-Hemmer: Glaube, Hoffnung, Wahrheit! Akt Rheumatol 23: 1-5
7. Brune K, Hinz B (1998) 2-Arylpropionsäuren: Stellenwert in der Schmerztherapie. Schmerz 12: 383-388
8. Brune K, Glatt M, Graf P (1976) Mechanism of action of antiinflammatory drugs. Gen Pharmacol 7: 27-33
9. Brune K, Rainsford KD, Schweitzer A (1980) Biodistribution of mild analgesics. Br J Clin Pharmacol 10 [Suppl] 2: 279-284
10. Brune K, Rainsford KD, Wagner K, Peskar BA (1981) Inhibition by anti-inflammatory drugs of prostaglandin production in cultured macrophages - factors influencing the apparent drug effects. Arch Pharmacol 315: 269-276
11. Chakraborty I, Das SK, Wang J, Dey SK (1996) Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 16: 107-122
12. Claria J, Serhan CN (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92: 9475-9479
13. Claria J, Lee MH, Serhan CN (1996) Aspirin-triggered lipoxins (15-epi-X) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 2: 583-596
14. Crofford LJ (1996) Expression and regulation of COX-2 in synovial tissues of arthritic patients. In: Vane JR, Botting JH, Botting RM (eds) Improved non-steroid anti-inflammatory drugs. COX-2 Enzyme Inhibitors. Kluwer and William Harvey Press, London, pp 133-146
15. Davidson FF, Dennis EA, Powell M, Glenney JR Jr (1987) Inhibition of phospholipase A2 by "lipocortins" and calpactins. An effect of binding to substrate phospholipids. J Biol Chem 262: 1698-1705
16. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Corry SA, Trzaskos JM (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378: 406-409
17. Distel M, Mueller C, Bluhmki E, Fries J (1996) Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 35: 68-77
18. Ehrich E, Mehlisch D, Perkins S, Brown P, Wittreich J et al (1996) Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain. Arthritis Rheum 39 [Suppl] 9: S81
19. Engelhardt G, Bögel R, Schnitzer C, Utzmann R (1996) Meloxicam: influence on arachidonic acid metabolism; part I: in vitro findings. Biochem Pharmacol 51: 21-28
20. Flower RJ, Vane JR (1972) Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature New Biol 240: 410-411
21. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737-16740
22. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316
23. Gibb W, Sun M (1996) Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua. J Endocrinol 150: 497-503
24. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K (1995) Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 305: 479-484
25. Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BA (1998) Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol 123: 927-935
26. Handwerker HO, Reeh PW (1991) Pain and inflammation. In: Bond M, Charlton JE, Woolf C (eds) Proceedings of the Vth World Congress on Pain. Pain Research and Clinical Management, vol. 5. Elsevier, North Holland, pp 59-70
27. Harris RC (1998) Potential roles of COX-2 in kidney physiology and disease. Second International Workshop on COX-2, July 28-31, 1998, Kapalua, Maui, Hawaii (Presentation Summaries)
28. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94: 2504-2510
29. Heppelmann B, Pfeffer A, Schaible H-G, Schmidt RF (1986) Effects of acetylsalicylic acid and indomethacin on single groups II and IV sensory units from acutely inflamed joints. Pain 26: 337-351
30. Hinz B, Hirschelmann R (1997) Neuere Erkenntnisse zur endogenen Regulation der Glucocorticoide. Pharmazie 52: 655-669
31. Hirschelmann R (1991) Nichtsteroidale Antiphlogistika. Entwicklung des Kenntnisstandes zum Wirkungsmechanismus. Med Mo Pharm 14: 100-108
32. Holtzman MJ, Turk J, Shornick LP (1992) Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem 267: 21438-21445
33. Hubbard RC, Koepp RJ, Yu S, Talwalker S, Geis GS, Wiesenhutter CW, Makarowski WS, Paulus HA (1996) SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum 39 [Suppl]: Abst 1188
34. Hubbard RC, Mehlisch DR, Jasper DR, Nugent MJ, Yu S, et al (1996) SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J Invest Med 44: 293A
35. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM (1993) The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 148: 1447-1451
36. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ (1998) Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 280: 1268-1270
37. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill G (1996) Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111: 445-454
38. Kawamori T, Rao CV, Seibert K, Reddy BS (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412
39. Kujuba DA, Herschman HR (1992) Dexamethasone inhibits mitogen induction of the TIS 10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 267: 7991-7994
40. Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399-4404
41. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak, JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384: 644-648
42. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271: 927-934
43. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483-492
44. Laporte JR, Carne X, Vidal X, Moreno V, Juan J (1991) Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan countries study on upper gastrointestinal bleeding. Lancet 337: 85-89
45. Levy GN (1997) Prostaglandin H synthases, nonsteroidal antiinflammatory drugs, and colon cancer. FASEB J 11: 234-247
46. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK (1997) Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91: 197-208
47. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Struct Biol 3: 927-933
48. Malmberg AB, Yaksh TL (1992) Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257: 1276-1279
49. Mancini JA, Vickers PJ, O'Neill GP, Boily C, Falgueyret JP, Riendeau D (1997) Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs. Mol Pharmacol 51: 52-60
50. Masferrer JL, Seibert K, Zweifel B, Needleman P (1992) Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 89: 3917-3921
51. Masferrer JL, Zweifel BS, Seibert S, Needleman P (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86: 1375-1379
52. Meade EA, Smith WL, DeWitt DL (1993) Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268: 6610-6614
53. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M (1997) Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112: 387-397
54. Niiro H, Otsuka T, Izuhara K, Yamaoka K, Ohshima K, Tanabe T, Hara S, Nemoto Y, Tanaka Y, Nakashima H, Niho Y (1997) Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 89: 1621-1628
55. O'Banion MK, Sadowski HB, Winn V, Young DA (1991) A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 266: 23261-23267
56. O'Neill GP, Ford-Hutchinson AW (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330: 156-160
57. Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, Chen QR, Seo H, Ohta H, Nozawa S, Kudo I, Suda T (1996) IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 156: 758-764
58. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809
59. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM (1997) Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10: 503-507
60. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J, Patrono C (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthase. J Pharmacol Exp Ther 271: 1705-1712
61. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C (1997) Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48: 623-631
62. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347-1365
63. Peri KG, Hardy P, Li DY, Varma DR, Chemtob S (1995) Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn. J Biol Chem 270: 24615-24620
64. Phelps P, McCarty DJ (1966) Suppression of crystal-induced synovitis in canine joints by indomethacin. Demonstration of inhibition of leucocyte mobility. Arthritis Rheum 9: 532
65. 2 synthase-1. Nature 367: 243-249
66. Rainsford KD, Schweitzer A, Brune K (1981) Autoradiographic and biochemical observations on the distribution of non-steroid antiinflammatory drugs. Arch Int Pharmacodyn Ther 250: 180-194
67. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280
68. 2-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 253: 3782-3784
69. Roth GJ, Siok CJ, Ozols J (1980) Structural characteristics of prostaglandin synthetase from sheep vesicular gland. J Biol Chem 255: 1301-1304
70. Sawdy R, Slater D, Fisk N, Edmonds DK, Bennett P (1997) Use of a cyclooxygenase type-2-selective nonsteroidal anti-inflammatory agent to prevent preterm delivery. Lancet 350: 265-266
71. Schaible H-G, Grubb BD (1993) Afferent and spinal mechanisms of joint pain. Pain 55: 5-54
72. Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff T, Flogerzi B, Halter F (1998) Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 123: 795-804
73. Serhan CN (1997) Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 53: 107-137
74. Sirois J, Richards JS (1992) Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 267: 6382-6388
75. Skidmore IF, Whitehouse MW (1966) Biochemical properties of anti-inflammatory drugs. VIII. Biochem Pharmacol 15: 1965
76. Smith WL, Marnett LJ (1991) Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1083: 1-17
77. 4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med 185: 1693-1704
78. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596
79. Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM (1997) Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol 144: 339-349
80. Topper JN, Cai J, Falb D, Gimbrone MA Jr (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93: 10417-10422
81. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501
82. Tsujii M, Kwano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716
83. Vane JR (1971 ) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 231: 232-235
84. Vane J (1994) Towards a better aspirin. Nature 367: 215-216
85. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120
86. Whitehouse MW (1964) Biochemical properties of antiinflammatory drugs. II. Uncoupling of oxidative phosphorylation in a connective tissue (cartilage) and liver mitochondria by salicylate analogues: relationship of structure to activity. Biochem Pharmacol 13: 319
87. Whittle BJ (1993) Thirteenth Gaddum Memorial Lecture. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br J Pharmacol 110: 3-17
88. Williams CS, Smalley W, DuBois RN (1997) Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 100: 1-5
89. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692-2696
90. Zakar T, Hirst JJ, Milovic JE, Olson DM (1995) Glucocorticoids stimulate the expression of prostaglandin endoperoxide H synthase-2 in amnion cells. Endocrinology 136: 1610-1619
91. Zembowicz A, Jones SL, Wu KK (1995) Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest 96: 1688-1692